Review Artikel : Pengembangan Valsartan dalam Meningkatkan Kelarutan dan Bioavailbilitas dalam Tubuh

SILVI RISTATIANTI, Anis Yohana Chaerunissa

Abstrak


Valsartan merupakan salah satu obat yang digunakan dalam terapi antihipertensi yang termasuk golongan angiotensin II reseptor blocker. Valsartan saat ini sangat banyak diproduksi mengingat prevalensi hipertensi yang tinggi, akan tetapi perkembangan produksi valsartan terbentur oleh sifat dari valsartan yang berbentuk amorf. Valsartan termasuk ke dalam salah satu obat golongan BCS  kelas III yang memiliki kelarutan dan permeabilitas yang rendah. Review ini, menjelaskan tentang  perkembangannya valsartan dibuat dalam bentuk kristal yang akan meningkatkan kelarutan yang berhubungan dengan bioavailbilitas. Selain itu, valsartan memiliki tiga pengotor yang sering terbawa dan dalam produksinya. Kesimpulannya, pengembangan sediaan obat valsartan dikembangkan dengan perubahan bentuk amorf menjadi kristal dengan solvasi dan co-crystal kemudian pengembangan dalam pemisahan pengotor dilakukan dengan HPLC yang dibantu oleh detektor NMR dan MS.


Teks Lengkap:

PDF

Referensi


Siddiqui N, Husain A, Chaudhry L, Alam MS, Mitra M, Bhasin PS, et al. 2011. Pharmacological and Pharmaceutical Profile of Valsartan : A Review.;1(4):12–9.

Mistri, Nisha et al. 2006. Evaluation D. The angiotensin receptor antagonist valsartan : a review of the literature with a focus on.;575–81.

Cubuk E, Cubuk B, Ozkan SA, Alsancak G. 2010. Journal of Pharmaceutical and Biomedical Analysis Combined effect of polarity and pH on the chromatographic behavior of some angiotensin II receptor antagonists and optimization of their determination in pharmaceutical dosage forms. J Pharm Biomed Anal [Internet].;53(3):475–82. Available from: http://dx.doi.org/10.1016/j.jpba.2010.05.020

Pozna PT, Pyda M. 2014. CHARACTERISATION OF VALSARTAN AND ITS COMPATIBILITY WITH BISOPROLOL STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY AND SOLID - STATE NUCLEAR MAGNETIC RESONANCE CHARAKTERYSTYKA WALSARTANU ORAZ BADANIE W FAZIE STAŁEJ.

Nalluri BN, M RK, Tp R, Crooks PA. 2012.Effect of Recrystallization on the Pharmaceutical Properties of Valsartan for Improved Therapeutic Efficacy.;2(10):126–32.

Adhiyaman R, Kumar S. 2006. Crystal modification of dipyridamole using different solvents and crystallization conditions.;321:27–34.

Tran TT, Tran PH, Park J, Lee B. 2012. Effects of Solvents and Crystallization Conditions on the Polymorphic Behaviors and Dissolution Rates of Valsartan.;35(7):1223–30.

Uchimoto T, Iwao Y, Takahashi K, Tanaka S, Agata Y, Iwamura T, et al. 2011. European Journal of Pharmaceutics and Biopharmaceutics A comparative study of glycerin fatty acid ester and magnesium stearate on the dissolution of acetaminophen tablets using the analysis of available surface area. Eur J Pharm Biopharm [Internet].;78(3):492–8. Available from: http://dx.doi.org/10.1016/j.ejpb.2011.01.014

Criscione L, Gasparo M De, Biihlmayer P, Whitebread S, Ramjoue HR, Wood J. 1993. Pharmacological profile of valsartan : a potent , orally active , nonpeptide antagonist of the angiotensin II AT , -receptor subtype.;761–71.

Thipparaboina R, Kumar D, Chavan RB, Shastri NR. 2016. Multidrug co-crystals : towards the development of effective therapeutic hybrids. Drug Discov Today [Internet].;21(3):481–90. Available from: http://dx.doi.org/10.1016/j.drudis.2016.02.001

Brittain HG. 2008. Polymorphism and Solvatomorphism.;97(9):3611–36.

Chikhalia V, Forbes RT, Storey RA, Ticehurst M. 2006. The effect of crystal morphology and mill type on milling induced crystal disorder. Eur J Pharm Sci 27:19–26.

Rani M, Govindarajan R, Surana R, Suryanarayanan R. 2006. Structure in dehydrated trehalose dihydrate—Evaluation of the concept of partial crystallinity. Pharm Res 23:2356–2367.

Lester C, Lubey G, Dicks M, Andol G, Vaugn D, Cambron RT, Poiesz K, Redman-Furey N. 2006. Dehydration of risedronate hemi-pentahydrate: Analytical and physical characterization. J Pharm Sci 95:2632–2644.

Taylor P, Nie J, Xiang B, Feng Y, Wang D. 2013. Journal of Liquid Chromatography & Related Isolation and Identification of Process Impurities in Crude Valsartan by HPLC , Mass Spectrometry , and Nuclear Magnetic Resonance Spectroscopy. (July):37–41.

Hillaert, S.; Bossche, W.V. 2002. Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A. 979, 323.

Waldmeier F., Flesh G., Muller P., Winkler T., Kriemler HP., Buhlmayer P., Gasparo MD. 1997. Pharmacokinetics disposition and biotransformation of [14C] radiolabelled valsartan in health male volunteers after a single oral dose. Xenobiotic; 27(1): 59-71.

Younus M., Reddy TK., Reddy YR., Arif MF. 2010. RP-HPLC Method Development and Validation for Simultaneous Estimation of Amlodipine besylate, Valsartan and Hydrochlorothiazide in Tablet Dosage form. J Pharmacy Res; 3(11): 2647-2650.

Iqbal M., Khuroo A., Batolar LS., Tandon M., Monif T., Sharma PL. 2010. Pharmacokinetics and Bioequivalence Study of Three Oral Formulations of Valsartan 160 mg A Single-Dose, Randomized, Open Label, Three-Period Crossover Comparison in Healthy Indian Male Volunteers. Clin Therapeutics; 32: 588-596.

Iriarte G., Ferreirós N., Ibarrondo I. Alonso RM., Maguregi MI., Gonzalez L., Jiménez RM. 2006. Optimization via experimental design of an SPE-HPLC-UV fluorescence method for the determination of valsartan and its metabolite in human plasma samples. J Separation Sci; 29(15): 2265-2283.

Kadam BR, Bari SB. 2007. Quantitative analysis of valsartan and hydrochlorothiazide in tablets by high performance thin-layer chromatography with ultraviolet absorption densitometry. Acta Chromatographica; 18: 260-269




DOI: https://doi.org/10.24198/jf.v17i1.18756

DOI (PDF): https://doi.org/10.24198/farmaka.v17i1.18756.g12863

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved